Business Context and Reporting Period
This Form 8-K reports on the annual stockholders' meeting of China Pharma Holdings, Inc. held on December 30, 2025. The meeting addressed matters related to the fiscal year ended December 31, 2024. The company is incorporated in Nevada and its common stock trades on the NYSE American under the symbol CPHI.
Key Financial Metrics
This filing is a current report regarding corporate governance and shareholder votes. It does not provide financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to the company's most recent Form 10-K or 10-Q for financial performance details.
Material Changes and Voting Results
A quorum was established with 3,501,046 shares present, representing approximately 69.71% of total outstanding shares. Three key proposals were submitted and approved:
- Election of Directors: Three independent director nominees were elected with overwhelming support:
- Gene Michael Bennett: 3,500,418 votes for, 628 withheld.
- Yingwen Zhang: 3,500,418 votes for, 628 withheld.
- Baowen Dong: 3,500,416 votes for, 630 withheld.
- Reverse Stock Split Authorization: Shareholders approved an amendment to the Articles of Incorporation to effect a reverse stock split at a ratio up to 1:20. The Board retains discretion on whether and when to implement this split.
- Compensation Plan Amendment: Amendment No. 3 to the Amended and Restated 2010 Long-Term Incentive Plan was approved (3,500,258 votes for, 774 against, 14 abstentions).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No specific risks or contingencies were disclosed in this document, other than the standard corporate governance actions taken.
Key Facts for Investor Verification
- Verify the current share count and whether the authorized 1:20 reverse stock split has been implemented by the Board.
- Confirm the effective date of the newly elected directors' terms.
- Review the specific terms of Amendment No. 3 to the 2010 Long-Term Incentive Plan to understand changes to executive compensation.
- Check subsequent filings for any financial updates, as this 8-K contains no financial performance data.